Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352423 | 0.99 | CA1 (0.38) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL29358193 | 0.99 | CA1 (0.38) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL19469294 | 0.95 | CA1 (0.36) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL28859005 | 0.91 | POLB (0.35) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL29355132 | 0.89 | POLB (0.36) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL12929986 | 0.89 | POLB (0.36) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL30966657 | 0.88 | POLB (0.35) | CA1CA2CA7CA9HDAC4 | |
| Trifluoromethanesulfonic Acid SCHEMBL30107006 | 0.87 | CA1 (0.36) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL20346570 | 0.85 | CA1 (0.33) | CA1CA2CA7CA9 | |
| SCHEMBL28513987 | 0.81 | ALDH1A1 (0.34) | CA1CA2CA7CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547663-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | F. Hoffmann-La Roche AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| US-20250115607-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4188551-B1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-12-18 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024003209-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-04 | — | — | WO | disclosed |
| EP-3532468-B1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AG (DE) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115607-A1 | PYRIDINE DERIVATIVES | ADORA1, CYP1A1, MT-ND1 | CA1 3526/4885CA2 2995/4885CA7 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.